Program
ibrutinib
Also written as “Ibrutinib”, “PCI-32765” and “PCI-32765 (Ibrutinib)”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Mantle-Cell · Waldenstrom Macroglobulinemia · Lymphoma, Large B-Cell, Diffuse · Multiple Myeloma, led by 5 companies.
Drug pageIbrutinib: every studyMany companies study it; this page follows only the 74 they lead. All 264 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 364 open or running | phase 4since Jun 14, 2017 | May 14, 2012 | Dec 31, 2026phase 3 · NCT01804686 |
| AbbVieits history only | 341 open or running | phase 4since Jun 5, 2017 | Feb 20, 2009 | May 10, 2027phase 4 · NCT03229200 |
| Novartisits history only | 21 open or running | phase 2since May 21, 2019 | Mar 13, 2019 | Jun 30, 2027phase 2 · NCT03960840 |
| BeOne Medicinesits history only | 10 open or running | phase 3since Feb 7, 2017 | Feb 7, 2017 | none ahead |
| Oncternal Therapeuticsits history only | 10 open or running | phase 3since Jun 9, 2022 | Jun 9, 2022 | none ahead |
Also a collaborator on its studies: Bristol-Myers Squibb.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Oct 9, 2012.
- Mar 6, 20182 phase 3 studiesJohnson & Johnson · NCT03462719, NCT03474679
- Dec 12, 2018Phase 2 study in Bronchiolitis Obliterans SyndromeAbbVie · NCT03790332 · 59 enrolled · United States, Australia, Austria and more
- Mar 12, 2019Phase 2 study in LeukemiaAbbVie · NCT03873493 · 14 enrolled · United States, Australia, Austria and more
- Mar 13, 2019Novartis’s first study: phase 1 study in Lymphoma, Large B-Cell, DiffuseNew to NovartisNovartis · NCT03876028 · 10 enrolled · United States
- May 21, 2019Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNovartis · NCT03960840 · 218 enrolled · United States, Australia, Austria and more
- Jul 31, 2019Phase 4 study in Waldenstrom MacroglobulinemiaJohnson & Johnson · NCT04042376 · 17 enrolled · China
- Aug 19, 2019Phase 2 study in Waldenstrom MacroglobulinemiaJohnson & Johnson · NCT04062448 · 16 enrolled · Japan
- May 4, 2020Phase 2 study in COVID-19AbbVie · NCT04375397 · 46 enrolled · United States
- Jul 17, 2020Phase 2 study in Lymphoma, Mantle-CellAbbVie · NCT04477486 · 13 enrolled · Japan
- Oct 25, 2021Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellAbbVie · NCT05105841 · 20 enrolled · Japan
- Jun 9, 2022Oncternal Therapeutics’ first study: phase 3 study in Lymphoma, Mantle-CellNew to Oncternal TherapeuticsOncternal Therapeutics · NCT05431179
- Sep 30, 2022Phase 2 study in Lymphoma, Mantle-CellJohnson & Johnson · NCT05564052 · 36 enrolled · Brazil, Czechia, Greece and more
- Jul 19, 2023Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellJohnson & Johnson · NCT05963074 · 333 enrolled · United States, Canada, Czechia and more
- Jan 16, 2025Phase 1 study in Leukemia, Myeloid, AcuteJohnson & Johnson · NCT06788509 · 120 planned · Australia, Belgium, Denmark and more
Ahead
- Dec 31, 2026Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellJohnson & Johnson · NCT01804686
- May 10, 2027Primary completion: phase 4 study in Lymphoma, B-CellAbbVie · NCT03229200
- Jun 30, 2027Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNovartis · NCT03960840
- Dec 15, 2027Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellJohnson & Johnson · NCT05963074
TargetBeta
“An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
The newest 60 of 74 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06788509Leukemia, Myeloid, Acute · Australia, Belgium, Denmark and more | 1 | By invitation | Johnson & Johnson | Jan 19, 2028 | 120 |
| NCT05963074Leukemia, Lymphocytic, Chronic, B-Cell · United States, Canada, Czechia and more | 2 | Active, not recruiting | Johnson & Johnson | Dec 15, 2027 | 333 |
| NCT05564052Lymphoma, Mantle-Cell · Brazil, Czechia, Greece and more | 2 | Completed | Johnson & Johnson | Dec 6, 2023 | 36 |
| NCT05431179Lymphoma, Mantle-Cell | 3 | Withdrawn | Oncternal Therapeutics | Nov 2026 | 0 |
| NCT05105841Leukemia, Lymphocytic, Chronic, B-Cell · Japan | 2 | Completed | AbbVie | Oct 9, 2025 | 20 |
| NCT04477486Lymphoma, Mantle-Cell · Japan | 2 | Completed | AbbVie | Feb 9, 2022 | 13 |
| NCT04375397COVID-19 · United States | 2 | Completed | AbbVie | May 10, 2021 | 46 |
| NCT04062448Waldenstrom Macroglobulinemia · Japan | 2 | Completed | Johnson & Johnson | Aug 24, 2021 | 16 |
| NCT04042376Waldenstrom Macroglobulinemia · China | 4 | Completed | Johnson & Johnson | Mar 19, 2024 | 17 |
| NCT03960840Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 2 | Active, not recruiting | Novartis | Jun 30, 2027 | 218 |
| NCT03876028Lymphoma, Large B-Cell, Diffuse · United States | 1 | Terminated | Novartis | Nov 1, 2021 | 10 |
| NCT03873493Leukemia · United States, Australia, Austria and more | 2 | Completed | AbbVie | Nov 4, 2021 | 14 |
| NCT03790332Bronchiolitis Obliterans Syndrome · United States, Australia, Austria and more | 2 | Completed | AbbVie | Oct 9, 2025 | 59 |
| NCT03474679Graft vs Host Disease · Japan | 3 | Completed | Johnson & Johnson | Nov 29, 2021 | 19 |
| NCT03462719Leukemia, Lymphocytic, Chronic, B-Cell · United States, Belgium, Canada and more | 3 | Active, not recruiting | Johnson & Johnson | Feb 26, 2021 | 211 |
| NCT03301207Leukemia, Lymphocytic, Chronic, B-Cell · Poland, Spain | 1 | Completed | Johnson & Johnson | Jul 17, 2018 | 25 |
| NCT03190330Leukemia, Lymphocytic, Chronic, B-Cell · India | 4 | Completed | Johnson & Johnson | May 3, 2023 | 75 |
| NCT03229200Lymphoma, B-Cell · United States, Australia, Canada and more | 4 | Active, not recruiting | AbbVie | May 10, 2027 | 297 |
| NCT03053440Waldenstrom Macroglobulinemia · United States, Australia, Czechia and more | 3 | Completed | BeOne Medicines | Jun 21, 2022 | 201 |
| NCT02947347Lymphoma, Follicular · United States, Australia, Austria and more | 3 | Completed | AbbVie | Feb 21, 2024 | 445 |
| NCT02959944Bronchiolitis Obliterans Syndrome · United States, Australia, Austria and more | 3 | Completed | AbbVie | Mar 27, 2020 | 193 |
| NCT02910583Leukemia · United States, Australia, Italy and more | 2 | Completed | AbbVie | Nov 12, 2020 | 323 |
| NCT02902965Multiple Myeloma · Czechia, Germany, Greece and more | 2 | Completed | AbbVie | Oct 26, 2018 | 74 |
| NCT02877225Healthy · United States | 1 | Completed | Johnson & Johnson | Nov 11, 2016 | 103 |
| NCT02841150Healthy · United States | 1 | Completed | Johnson & Johnson | Aug 2016 | 102 |
| NCT02703272Lymphoma, Non-Hodgkin · United States, Belgium, Brazil and more | 3 | Terminated | Johnson & Johnson | Jun 11, 2021 | 72 |
| NCT02638116Healthy · Belgium | 1 | Completed | Johnson & Johnson | Mar 2016 | 20 |
| NCT02599324Carcinoma, Renal Cell · United States, Korea, Republic of, Spain and more | 2 | Completed | AbbVie | Aug 20, 2021 | 263 |
| NCT02548962Multiple Myeloma · United States, Australia, Czechia and more | 2 | Terminated | AbbVie | Jun 13, 2018 | 11 |
| NCT02556892Leukemia, Lymphoid · Japan | 1 | Completed | Johnson & Johnson | Aug 20, 2018 | 8 |
| NCT02436668Metastatic Pancreatic Adenocarcinoma · United States, Belgium, France and more | 3 | Completed | AbbVie | Oct 2018 | 430 |
| NCT02390609Healthy · Belgium | 1 | Completed | Johnson & Johnson | Nov 2015 | 40 |
| NCT02381080Leukemia, Lymphocytic, Chronic, B-Cell · Canada, Russian Federation, Spain | 1 | Completed | Johnson & Johnson | Jun 24, 2016 | 26 |
| NCT02351037Leukemia, Myeloid, Acute · United States | 2 | Terminated | AbbVie | Apr 2017 | 36 |
| NCT02329847Hematologic Neoplasms · United States, Australia, Israel and more | 2 | Completed | Johnson & Johnson | Feb 9, 2022 | 144 |
| NCT02271438Healthy · Belgium | 1 | Completed | Johnson & Johnson | Apr 2015 | 28 |
| NCT02264574Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Completed | AbbVie | Mar 26, 2018 | 229 |
| NCT02195869Graft vs Host Disease · United States | 2 | Completed | AbbVie | Sep 15, 2017 | 45 |
| NCT02169180Lymphoma, Mantle-Cell · Japan | 2 | Completed | Johnson & Johnson | Nov 2016 | 16 |
| NCT02165397Waldenstrom Macroglobulinemia · United States, Australia, Canada and more | 3 | Completed | AbbVie | Nov 7, 2019 | 181 |
| NCT02142049Lymphoma · United States | 2 | Completed | AbbVie | Aug 2017 | 35 |
| NCT02077166Lymphoma, Large B-Cell, Diffuse · United States, Belgium, Germany and more | 2 | Completed | AbbVie | Dec 17, 2020 | 138 |
| NCT01980628Lymphoma, B-Cell, Marginal Zone · United States, Belgium, France and more | 2 | Completed | AbbVie | Jul 2016 | 63 |
| NCT01974440Lymphoma · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | May 30, 2022 | 403 |
| NCT01973387Leukemia, Lymphocytic, Chronic, B-Cell · Australia, China, Malaysia and more | 3 | Completed | Johnson & Johnson | Dec 1, 2015 | 160 |
| NCT01980654Lymphoma, Follicular · United States | 2 | Completed | AbbVie | Nov 2017 | 80 |
| NCT01962792Multiple Myeloma · United States, Canada | 2 | Completed | AbbVie | Mar 2019 | 84 |
| NCT01969266Healthy Volunteer · United States | 1 | Completed | Johnson & Johnson | Nov 2013 | 8 |
| NCT01866033Healthy Volunteer · Belgium | 1 | Completed | Johnson & Johnson | Aug 2013 | 8 |
| NCT01855750Lymphoma · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | Feb 26, 2018 | 838 |
| NCT01820936Healthy Volunteers · United States | 1 | Completed | Johnson & Johnson | Jun 2013 | 52 |
| NCT01804686Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Dec 31, 2026 | 539 |
| NCT01779791Lymphoma · United States, Australia, Belgium and more | 2 | Completed | Johnson & Johnson | May 18, 2016 | 110 |
| NCT01776840Lymphoma, Mantle-Cell · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | Jun 30, 2021 | 523 |
| NCT01767948Hepatic Impairment · United States | 1 | Completed | Johnson & Johnson | Nov 2013 | 30 |
| NCT01763021Healthy Participants · United States | 1 | Completed | Johnson & Johnson | Jan 2013 | 18 |
| NCT01744691Chronic Lymphocytic Leukemia With 17p Deletion · United States, Australia, Belgium and more | 2 | Completed | AbbVie | Jun 2014 | 145 |
| NCT01724346Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more | 3 | Completed | AbbVie | Aug 18, 2023 | 269 |
| NCT01722487Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more | 3 | Completed | AbbVie | May 2015 | 269 |
| NCT01704963Neoplasms · Japan | 1 | Completed | Johnson & Johnson | Nov 20, 2015 | 15 |
How it is read
Names in the registry
- “Ibrutinib”, 49 entries
- “PCI-32765”, 10 entries
- “ibrutinib”, 6 entries
- “PCI-32765 (Ibrutinib)”, 2 entries
- “SNX-5422 plus ibrutinib”, 2 entries
Codes read as this program: PCI32765.
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 23 studies
- Lymphoma, Mantle-Cell, 8 studies
- Waldenstrom Macroglobulinemia, 5 studies
- Lymphoma, Large B-Cell, Diffuse, 4 studies
- Multiple Myeloma, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.